Biomarkers - Market Insights, Competitive Landscape, and Market Forecast - 2030

The global biomarkers market was valued at USD 47.17 billion in 2023, growing at a CAGR of 9.06% during the forecast period from 2024 to 2030 to reach USD 86.40 billion by 2030. The demand for biomarkers is primarily being boosted by the increasing prevalence of chronic diseases globally, the growing need for early detection and personalized medicine, and the increasing importance of companion diagnostics, during the forecast period from 2024 to 2030.

Biomarkers Market Dynamics:

According to the data published by the World Health Organization (WHO) in 2023, non-communicable diseases kill 41 million people each year, equivalent to 74% of all deaths globally. Each year, 17 million people die from non-communicable diseases before age 70; 86% of these premature deaths occur in low- and middle-income countries. Moreover, according to the same source mentioned above, cardiovascular diseases account for most non-communicable deaths, or 17.9 million people annually, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million including kidney disease deaths caused by diabetes). These four groups of diseases account for over 80% of all premature non-communicable deaths.

On the other hand, the launch of biomarker tests by the market players is also augmenting the market's growth. For instance, in April 2024, Labcorp launched a first-of-its-kind test for glial fibrillary acidic protein (GFAP), a critical blood-based biomarker for the early detection of neurodegenerative diseases and neurological injuries. The new GFAP test offered physicians a more efficient pathway to assess the presence and progression of neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, glioblastoma, and injuries like traumatic brain injury (TBI).

Moreover, in recent years, there has been a paradigm shift in healthcare towards early detection and personalized medicine. Early detection of diseases offers several advantages, including better treatment outcomes, reduced healthcare costs, and improved patient survival rates. Biomarkers, as measurable indicators of biological processes, play a crucial role in enabling early detection by providing insights into disease onset, progression, and response to treatment.

Personalized medicine aims to customize medical treatment based on each patient's genetic makeup, lifestyle, and disease biomarkers. Biomarkers play a crucial role in personalized medicine by identifying patient subgroups that are likely to benefit from specific treatments, predicting treatment responses, and guiding therapeutic decision-making.

Due to factors such as the increasing prevalence of life-threatening diseases, the growing use of biomarkers in disease diagnosis, and rising product launches, the demand for biomarkers is expected to increase, leading to overall growth in the biomarkers market.

However, the growing disease complexity and heterogeneity and high cost associated with biomarkers may act as factors that are expected to limit the growth of the biomarkers market.

Biomarkers Market Segment Analysis:

Biomarkers Market by Type (Safety Biomarkers, Efficacy Biomarkers, Predictive Biomarkers, Surrogate Biomarkers, and Others), Disease (Cancer, Cardiovascular, Neurological, Immunological, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment of the biomarkers market, the safety biomarkers category is estimated to amass a significant revenue share in the biomarkers market in 2023. This can be attributed to their pivotal role in ensuring patient safety throughout the drug development process. Regulatory agencies mandate the evaluation of safety biomarkers to assess potential drug toxicities and mitigate safety risks, driving their widespread adoption in preclinical and clinical studies. Moreover, the increasing complexity of drug candidates, the emergence of personalized medicine, and the growing focus on predictive toxicology further underscore the importance of safety biomarkers in drug development, solidifying their dominant position in the biomarkers market.

On the other hand, an increase in the population at high risk of developing various diseases, such as cancer, cardiovascular conditions, and kidney disorders, is expected to positively influence the market. Growing awareness of routine health checkups and lower drug attrition rates, which have been linked to biomarker-based therapies, and improving regulatory compliance positions safety biomarkers as a dominant category in the biomarkers market.

As per the 2024 report by the World Health Organization (WHO), breast cancer emerged as the most prevalent cancer among women in 157 out of 185 countries in 2022. During the same period, there were 2.3 million reported cases of breast cancer globally, resulting in 670,000 deaths. Breast cancer can affect women worldwide following puberty, with rates escalating in later stages of life. This widespread incidence of cancer fuels the demand for biomarkers.

Thus, given the ongoing prevalence of cancers and their role in ensuring the safety and efficacy of drugs throughout the drug development process, from early discovery to post-market surveillance. Their importance in safeguarding patient safety, and reducing development risks, this category is poised to propel the overall growth of the biomarkers market during the forecast period.

North America Is Expected To Dominate The Overall Biomarkers Market:

North America is expected to account for the highest proportion of the biomarkers market in 2023, out of all regions. This is due to the significant burden of chronic diseases such as cancer, Alzheimer’s disease, and others in the region. Additionally, the presence of key players is also anticipated to increase the penetration of novel biomarkers. Major players operating in the market include Abbott, Merck & Co., Inc., Johnson & Johnson Services, Inc., Thermo Fisher Scientific, Inc., and Bio-Rad Laboratories, Inc. Further, many academic institutions, research centers, and universities are collaborating with key market players to develop biomarkers for diagnosing and monitoring numerous diseases. These are some of the key factors driving the growth of the Biomarkers market in North America.

According to the American Cancer Society's Cancer Facts and Figures 2024 report, approximately 2 million new cancer cases are expected to be diagnosed in 2024 in the United States alone. Among these, prostate cancer is estimated at 299,010 cases, followed by lung cancer at 234,580 cases, and female breast cancer at 310,720 cases, demonstrating a rapid increase in the incidence of cancer cases in the country.

Further, according to the Alzheimer’s Association facts and figures published in 2024, nearly 7 million Americans have Alzheimer's, an estimated 6.9 million Americans age 65 and older are living with Alzheimer's and about 1 in 9 people age 65 and older (10.9%) have Alzheimer's. Moreover, according to the same organization, by 2050, the number of people age 65 and older with Alzheimer's may grow to a projected 12.7 million, barring the development of medical breakthroughs to prevent or cure Alzheimer's disease.

As biomarkers have broad applications in diagnosing and treating chronic diseases such as cancer, neurological disorders, and others, the demand for biomarkers is expected to increase in the country.

Thus, the rising incidence of cancer and neurological disorders in North America along with the various collaborations and presence of key players will eventually drive the overall market for Biomarkers in North America during the forecast period.

Biomarkers Market Key Players:

Some of the key market players operating in the Biomarkers market include F. Hoffmann-La Roche Ltd, Merck KGaA, Quibim, Quanterix, Abbott, QIAGEN, Revvity, Laboratory Corporation of America® Holdings, Charles River Laboratories., Bio-Rad Laboratories, Inc., Eurofins Scientific, BIOMÉRIEUX, Agilent Technologies, Inc., JSR Life Sciences, LLC, MESO SCALE DIAGNOSTICS, LLC., EKF Diagnostics, Celerion, Standard BioTools™, R-Biopharm AG, StressMarq Biosciences Inc., and others.

Recent Developmental Activities In The Biomarkers Market:

• In January 2024, Quibim and Merck KGaA partnered to develop diagnostic tools to develop the next generation of precision medicine technology targeting a wide range of cancers.
• In October 2023, Quanterix Corporation announced a new agreement with Janssen Sciences Ireland UC, a Johnson & Johnson Company to advance blood-based Alzheimer's disease detection. Under this agreement, Quanterix will receive worldwide, non-exclusive rights to Janssen’s extensively studied p-Tau 217 antibodies and assay designs for potential use in clinical research and diagnostic products, further strengthening Quanterix’s position at the forefront of the Alzheimer’s disease biomarker field.
• In February 2023, F. Hoffmann-La Roche Ltd launched the IDH1 R132H (MRQ-67) rabbit monoclonal primary antibody and the ATRX rabbit polyclonal antibody to identify mutation status in patients diagnosed with brain cancer.

Key Takeaways From The Biomarkers Market Report Study

• Market size analysis for current Biomarkers Market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the global Biomarkers market.
• Various opportunities are available for the other competitors in the Biomarkers Market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current Biomarkers market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Biomarkers market growth in the coming future?

Target Audience Who Can Be Benefited From This Biomarkers Market Report Study

• Biomarkers product providers
• Research organizations and consulting companies
• Biomarkers related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Biomarkers
• Various end-users who want to know more about the Biomarkers Market and the latest technological developments in the Biomarkers Market.

Frequently Asked Questions For The Biomarkers Market:

1. What are Biomarkers?

Biomarkers are measurable indicators that reflect normal biological processes, pathogenic processes, or pharmacological responses to therapeutic interventions. These markers can be found in various biological samples such as blood, urine, tissue, saliva, or cerebrospinal fluid.

2. What is the market for Antibody Drug Conjugate?

The global biomarkers market was valued at USD 47.17 billion in 2023, growing at a CAGR of 9.06% during the forecast period from 2024 to 2030 to reach USD 86.40 billion by 2030.

3. What are the drivers for the global Biomarkers market?

The Biomarkers Market is slated to witness prosperity owing to the increasing prevalence of chronic diseases globally, the growing need for early detection and personalized medicine, and the increasing importance of companion diagnostics, during the forecast period from 2024 to 2030.

4. Who are the key players operating in the global Biomarkers market?

Some of the key market players operating in the Biomarkers include F. Hoffmann-La Roche Ltd, Merck KGaA, Quibim, Quanterix, Abbott, QIAGEN, Revvity, Laboratory Corporation of America® Holdings, Charles River Laboratories., Bio-Rad Laboratories, Inc., Eurofins Scientific, BIOMÉRIEUX, Agilent Technologies, Inc., JSR Life Sciences, LLC, MESO SCALE DIAGNOSTICS, LLC., EKF Diagnostics, Celerion, Standard BioTools™, R-Biopharm AG, StressMarq Biosciences Inc., and others.

5. Which region has the highest share in the global Biomarkers market?

North America is expected to dominate the overall Biomarkers market during the forecast period from 2024 to 2030. This is due to the significant burden of chronic diseases such as cancer, Alzheimer’s disease, and others in the region. Additionally, the presence of key players is anticipated to increase the penetration of novel biomarkers are some of the key factors driving the growth of the Biomarkers market in North America.


This product will be delivered within 2 business days.